midazolam and erythromycin

midazolam has been researched along with erythromycin in 75 studies

Research

Studies (75)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.33)	18.7374
1990's	20 (26.67)	18.2507
2000's	35 (46.67)	29.6817
2010's	17 (22.67)	24.3611
2020's	2 (2.67)	2.80

Authors

Authors	Studies
Beck, WT; Schuetz, EG; Schuetz, JD	1
Fukuda, T; Hasegawa, R; Murakami, T; Nagai, J; Takano, M; Yumoto, R	1
Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ	1
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA	1
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A	1
Jolivette, LJ; Nagilla, R; Ward, KW	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Abraham, MH; Acree, WE; Ibrahim, A	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J	1
de Sousa, G; Domingo, M; Dou, M; Lacarelle, B; Lafont, H; Lechene de la Porte, P; Placidi, M; Rahmani, R	1
Wood, M	1
Hiller, A; Isohanni, P; Olkkola, KT; Saarnivaara, L	1
Barra, Y; Cano, JP; Covo, J; Crevat-Pisano, P; Dragna, S; Fabre, G	1
Benedict, PE; Berent, S; Lown, KS; Shen, DD; Thummel, KE; Turgeon, DK; Watkins, PB	1
Ring, BJ; Wrighton, SA	1
Watkins, PB	2
Idänpään-Heikkilä, JJ; Mattila, MJ; Vanakoski, J	1
Gonzalez, FJ; Korzekwa, KR; Nemec, J; Relling, MV; Schuetz, EG; Schuetz, JD	1
Idänpään-Heikkilä, JJ; Mattila, MJ; Törnwall, M; Vanakoski, J	1
Aranko, K; Hiller, A; Himberg, JJ; Luurila, H; Neuvonen, PJ; Olkkola, KT; Saarnivaara, L	1
Benhamou, D; Elhaddoury, M; Fernandez, H; Locatelli, C; Narchi, P	1
Laufen, H; Leitold, M; Scharpf, F; Wildfeuer, A; Yeates, RA; Zimmermann, T	1
Mattila, MJ; Seppälä, T; Vanakoski, J	1
Cerimele, B; DeSante, K; Goldberg, MJ; Hatcher, B; Ring, B; Sides, G; Wrighton, S	1
Laufen, H; Schumacher, T; Yeates, RA; Zimmermann, T	1
Groopman, JD; Kim, RB; Kinirons, MT; O'Shea, D; Thummel, KE; Wilkinson, GR; Wood, AJ	1
Antonello, S; Brucker, MJ; Carides, A; Gertz, BJ; Gillen, L; McCrea, J; Miller-Stein, C; Osborne, B; Prueksaritanont, T; Waldman, S	1
Iga, T; Kotaki, H; Matsuo, H; Sawada, Y; Takedomi, S; Yamamoto, K; Yamano, K	1
Brucker, MJ; Gagliano, K; Gillen, L; Greenberg, HE; McLoughlin, D; Prueksaritanont, T; Rogers, JD; Vega, JM; Waldman, SA; Wong, PH	1
Murakami, T; Nagai, J; Nasu, R; Sanemasa, M; Takano, M; Yumoto, R	1
Iga, T; Katashima, M; Kotaki, H; Matsuo, H; Ohtani, H; Sawada, Y; Takedomi, S; Yamamoto, K; Yamano, K	1
Matsuo, H; Ohtani, H; Sawada, Y; Takedomi, S; Yamano, K	1
Emoto, C; Iketaki, H; Nakajima, M; Satoh, T; Shimada, N; Shimizu, R; Suzuki, S; Yamasaki, S; Yamazaki, H; Yokoi, T	1
Danhof, M; Groeneveld, AB; Swart, EL; Touw, DJ; van der Hoven, B	1
Benet, LZ; Cummins, CL; Wu, CY	1
Ito, K; Itoh, T; Kanamitsu, S; Ogihara, K	1
Burke, JP; Dorval, EP; Gillen, LP; Greenberg, HE; Hauck, WW; Pequignot, E; Veronese, ML; Waldman, SA	1
Bhat, K; Floyd, MD; George, AL; Gervasini, G; Kim, RB; Masica, AL; Mayo, G; Wilkinson, GR	1
Dorval, EP; Gillen, LP; Greenberg, HE; Hauck, WW; Veronese, ML; Waldman, SA	1
Baba, T; Kanazu, T; Koike, M; Okamura, N; Yamaguchi, Y	1
de Bruijn, P; de Jong, FA; Figg, WD; Friberg, LE; Graveland, WJ; Lepper, ER; Mathijssen, RH; Rietveld, T; Sparreboom, A; van Schaik, RH; Verweij, J	1
Adams, M; Ahdieh, H; Gammaitoni, AR; Pieniaszek, HJ	1
Cheng, ZN; Li, HD; Li, KY; Li, X	1
Chaudhary, A; Drijfhout, WJ; Garner, RC; Jochemsen, R; Kneer, J; Kuhnz, W; Lappin, G; Oosterhuis, B; Rowland, M	1
Kurnik, D; Wilkinson, GR; Wood, AJ	1
Nakamura, K; Okazaki, O; Okudaira, N; Sudo, K; Watanabe, A	1
Imai, H; Kotegawa, T; Nakano, S; Ohashi, K; Okudaira, T; Tsutsumi, K	1
Blough, DK; Dees, EC; Givens, RC; Hawke, RL; Isoherranen, N; Iwanaga, K; Lamba, JK; Ludington, SR; Paine, MF; Pusek, SN; Schuetz, EG; Thummel, KE; Watkins, PB	1
Boulenc, X; Hachad, H; Levy, RH; Ragueneau-Majlessi, I; Rauch, C	1
Baker, SD; Franke, RM; Mathijssen, RH; Schuetz, EG; Sparreboom, A	1
Galinsky, RE; Hall, SD; Jones, DR; Kimura, RE; Quinney, SK; Zhang, X	1
Hayashi, Y; Helmi, AR; Khalil, WF; Motoyama, S; Sasaki, K; Shah, SS; Shimoda, M	1
Agrawal, V; Choi, JH; Giacomini, KM; Miller, WL	1
Baker, SD; Figg, WD; Franke, RM; Gibson, AA; Kosloske, AM; Lancaster, CS; Mathijssen, RH; Orwick, SJ; Peer, CJ; Sparreboom, A	1
Baba, T; Kadono, K; Kanazu, T; Sato, N; Takeda, Y; Touchi, A; Yamaguchi, Y	1
Senthilkumaran, S; Subramanian, PT	1
Becka, M; Kubitza, D; Mueck, W	1
Charles, KA; Clarke, SJ; de Graan, AJ; Elens, L; Haufroid, V; Mathijssen, RH; Nieuweboer, AJ; van Gelder, T; van Schaik, RH	1
Charles, KA; Clarke, SJ; de Graan, AJ; Elens, L; Haufroid, V; Mathijssen, RH; Nieuweboer, A; van Schaik, RH	1
Lanzarotti, C; Rossi, G	1
Calvert, H; Fettner, S; Hamilton, M; Ling, J; Lum, BL; Pantze, M; Plummer, R; Rakhit, A; Ranson, M; Twelves, C	1
Akiyoshi, T; Imaoka, A; Ishikawa, Y; Ohtani, H	1
Cahn, AP; Georgiou, A; Harrell, AW; Hessel, EM; Marotti, M; Patel, A; Riddell, K; Taskar, KS; Taylor, M; Tracey, H; Wilson, R	1
Chan, TS; Raymond, K; Scaringella, YS; Taub, ME	1

Reviews

4 review(s) available for midazolam and erythromycin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 1994, Volume: 4, Issue:4 Topics: Animals; Breath Tests; Cytochrome P-450 Enzyme System; Dapsone; Erythromycin; Humans; Hydrocortisone; Lidocaine; Liver; Midazolam; Nifedipine	1994
Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:5 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Humans; Metabolic Clearance Rate; Midazolam; Sex Characteristics	2002
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:6 Topics: Breath Tests; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythromycin; Female; Genotype; Haplotypes; Hepatocytes; Heterozygote; Humans; In Vitro Techniques; Male; Midazolam; Molecular Probe Techniques; Neoplasms; Organic Anion Transporters, Sodium-Independent; Pharmacogenetics; Risk Factors; Sensitivity and Specificity; Solute Carrier Organic Anion Transporter Family Member 1B3	2008

Trials

22 trial(s) available for midazolam and erythromycin

Article	Year
Azithromycin does not alter the effects of oral midazolam on human performance. European journal of clinical pharmacology, 1994, Volume: 47, Issue:1 Topics: Adult; Arousal; Azithromycin; Cross-Over Studies; Double-Blind Method; Drug Synergism; Erythromycin; Female; Humans; Male; Midazolam; Psychomotor Performance	1994
Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacology & toxicology, 1993, Volume: 73, Issue:3 Topics: Administration, Oral; Adult; Brain; Capsules; Double-Blind Method; Drug Combinations; Drug Synergism; Erythromycin; Female; Humans; Male; Midazolam; Psychomotor Performance; Roxithromycin; Triazolam	1993
A potentially hazardous interaction between erythromycin and midazolam. Clinical pharmacology and therapeutics, 1993, Volume: 53, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Double-Blind Method; Drug Synergism; Erythromycin; Female; Humans; Injections, Intravenous; Male; Midazolam; Psychomotor Performance; Reference Values	1993
Interactions of pre-operative erythromycin administration with general anaesthesia. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1993, Volume: 40, Issue:5 Pt 1 Topics: Adult; Alfentanil; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, General; Double-Blind Method; Drug Interactions; Erythromycin; Female; Gastric Acid; Gastrointestinal Contents; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Laparoscopy; Midazolam; Placebos; Premedication; Propofol; Prospective Studies	1993
Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittel-Forschung, 1996, Volume: 46, Issue:2 Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cross-Over Studies; Drug Interactions; Erythromycin; Female; Half-Life; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Psychomotor Performance; Sleep	1996
Grapefruit juice does not enhance the effects of midazolam and triazolam in man. European journal of clinical pharmacology, 1996, Volume: 50, Issue:6 Topics: Adult; Beverages; Citrus; Cross-Over Studies; Double-Blind Method; Erythromycin; Female; Food-Drug Interactions; Humans; Hypnotics and Sedatives; Male; Midazolam; Psychomotor Performance; Triazolam	1996
Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo. Journal of clinical pharmacology, 1996, Volume: 36, Issue:12 Topics: Adult; Anti-Anxiety Agents; Anti-Bacterial Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Half-Life; Histamine H1 Antagonists; Humans; Hydroxylation; Macrolides; Male; Microsomes, Liver; Midazolam; Middle Aged; Oxidoreductases, N-Demethylating; Spectrophotometry, Ultraviolet; Terfenadine	1996
Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. International journal of clinical pharmacology and therapeutics, 1997, Volume: 35, Issue:12 Topics: Anti-Anxiety Agents; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam	1997
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clinical pharmacology and therapeutics, 1999, Volume: 66, Issue:3 Topics: Adult; Anti-Anxiety Agents; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Female; Humans; Hydrocortisone; Linear Models; Male; Midazolam; Oxidoreductases, N-Demethylating; Phenotype; Protein Synthesis Inhibitors; Reference Values; White People	1999
Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. Journal of clinical pharmacology, 1999, Volume: 39, Issue:12 Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Male; Midazolam; Oxidoreductases, N-Demethylating; Reproducibility of Results	1999
Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. Journal of clinical pharmacology, 2000, Volume: 40, Issue:11 Topics: Administration, Oral; Adult; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Erythromycin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Midazolam; Oxidoreductases, N-Demethylating; Simvastatin; Single-Blind Method	2000
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. Journal of clinical pharmacology, 2003, Volume: 43, Issue:8 Topics: Adult; Area Under Curve; Beverages; Biological Availability; Breath Tests; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Gastrointestinal Agents; Half-Life; Humans; Hypnotics and Sedatives; Intestines; Liver; Male; Metabolic Clearance Rate; Midazolam	2003
Effect of mibefradil on CYP3A4 in vivo. Journal of clinical pharmacology, 2003, Volume: 43, Issue:10 Topics: Adult; Breath Tests; Carbon Radioisotopes; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Erythromycin; Humans; Intestines; Liver; Male; Metabolic Clearance Rate; Mibefradil; Midazolam; Molecular Probes; Single-Blind Method	2003
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. Journal of clinical pharmacology, 2005, Volume: 45, Issue:3 Topics: Adolescent; Adult; Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam; Middle Aged; Naltrexone; Oxymorphone; Rifampin; Tolbutamide	2005
Metabolic mechanism of quetiapine in vivo with clinical therapeutic dose. Methods and findings in experimental and clinical pharmacology, 2005, Volume: 27, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dibenzothiazepines; Enzyme Inhibitors; Erythromycin; Female; Humans; Male; Midazolam; Middle Aged; Quetiapine Fumarate; Schizophrenia	2005
Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clinical pharmacology and therapeutics, 2006, Volume: 80, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Area Under Curve; Carbon Radioisotopes; Chromatography, Liquid; Cross-Over Studies; Diazepam; Dose-Response Relationship, Drug; Drug Monitoring; Erythromycin; Estradiol; Female; GABA Modulators; Humans; Injections, Intravenous; Male; Mass Spectrometry; Midazolam; Middle Aged; Warfarin	2006
The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clinical pharmacology and therapeutics, 2006, Volume: 80, Issue:3 Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breath Tests; Cross-Over Studies; Cytochrome P-450 CYP3A; Double-Blind Method; Enzyme Inhibitors; Erythromycin; GABA Modulators; Humans; Infusions, Intravenous; Injections, Intravenous; Liver; Male; Metabolic Clearance Rate; Midazolam; Quinolines; Reproducibility of Results; Time Factors	2006
Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. Journal of clinical pharmacology, 2007, Volume: 47, Issue:7 Topics: Adult; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Drug Synergism; Erythromycin; Humans; Male; Midazolam; Time Factors	2007
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. British journal of clinical pharmacology, 2013, Volume: 76, Issue:3 Topics: Adolescent; Adult; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Metabolic Clearance Rate; Midazolam; Middle Aged; Morpholines; Rivaroxaban; Substrate Specificity; Thiophenes; Young Adult	2013
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:10 Topics: Adult; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Administration Schedule; Drug Interactions; Erythromycin; Humans; Male; Midazolam; Middle Aged; Neurokinin-1 Receptor Antagonists; Pyridines; Young Adult	2013
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anti-cancer drugs, 2014, Volume: 25, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Erythromycin; Female; Humans; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Middle Aged; Neoplasms; Quinazolines	2014
Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations. Drug metabolism and disposition: the biological fate of chemicals, 2020, Volume: 48, Issue:4 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Area Under Curve; Clarithromycin; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Healthy Volunteers; Humans; Indazoles; Indoles; Itraconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Models, Biological; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Prospective Studies; Retrospective Studies; Young Adult	2020

Other Studies

49 other study(ies) available for midazolam and erythromycin

Article	Year
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Molecular pharmacology, 1996, Volume: 49, Issue:2 Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Northern; Cell Line; Clotrimazole; Colonic Neoplasms; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dexamethasone; DNA Primers; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Midazolam; Mixed Function Oxygenases; Molecular Sequence Data; Multigene Family; Phenobarbital; Phenytoin; Polymerase Chain Reaction; Rifampin; Tumor Cells, Cultured; Verapamil	1996
Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. European journal of pharmacology, 1998, Oct-09, Volume: 358, Issue:3 Topics: Anti-Bacterial Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; GABA Modulators; Humans; Ketoconazole; Midazolam; Oxidoreductases, N-Demethylating; Rhodamine 123; Substrate Specificity; Vasodilator Agents; Verapamil	1998
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical research, 1999, Volume: 16, Issue:3 Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity	1999
Rational use of in vitro P-glycoprotein assays in drug discovery. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera	2001
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. Journal of medicinal chemistry, 2003, Apr-24, Volume: 46, Issue:9 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine	2003
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica; the fate of foreign compounds in biological systems, 2005, Volume: 35, Issue:2 Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs. European journal of medicinal chemistry, 2008, Volume: 43, Issue:3 Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization	2008
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorganic & medicinal chemistry, 2009, Oct-01, Volume: 17, Issue:19 Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity. Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1 Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water	2018
Thawed human hepatocytes in primary culture. Cryobiology, 1992, Volume: 29, Issue:4 Topics: Biotransformation; Cell Survival; Cells, Cultured; Cryopreservation; Erythromycin; Humans; Liver; Microscopy, Electron; Midazolam; Protein Biosynthesis; Proteins	1992
Midazolam and erythromycin. British journal of anaesthesia, 1991, Volume: 67, Issue:1 Topics: Child; Cytochrome P-450 Enzyme Inhibitors; Erythromycin; Humans; Midazolam	1991
Unconsciousness associated with midazolam and erythromycin. British journal of anaesthesia, 1990, Volume: 65, Issue:6 Topics: Adenoidectomy; Child; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam; Premedication; Unconsciousness	1990
Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochemical pharmacology, 1988, May-15, Volume: 37, Issue:10 Topics: Animals; Cyclosporins; Cytochrome P-450 Enzyme System; Enzyme Induction; Erythromycin; In Vitro Techniques; Isoenzymes; Male; Microsomes, Liver; Midazolam; Rabbits; Rifampin; Troleandomycin	1988
The erythromycin breath test predicts the clearance of midazolam. Clinical pharmacology and therapeutics, 1995, Volume: 57, Issue:1 Topics: Adult; Breath Tests; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Female; Half-Life; Humans; Injections, Intravenous; Male; Memory; Metabolic Clearance Rate; Midazolam; Predictive Value of Tests; Psychometrics; Sex Factors	1995
Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceutical research, 1994, Volume: 11, Issue:6 Topics: Chromatography, High Pressure Liquid; Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Nizatidine	1994
O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Molecular pharmacology, 1994, Volume: 45, Issue:2 Topics: Biotransformation; Catalysis; Catechols; Chromatography, High Pressure Liquid; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Erythromycin; Etoposide; Humans; Methylation; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Teniposide	1994
Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. The Journal of pharmacology and experimental therapeutics, 2000, Volume: 292, Issue:3 Topics: Animals; Blood Proteins; Diltiazem; Drug Interactions; Erythromycin; Hypnotics and Sedatives; Liver; Male; Midazolam; Protein Binding; Rats; Rats, Sprague-Dawley; Verapamil	2000
Erythromycin breath test. Clinical pharmacology and therapeutics, 2000, Volume: 67, Issue:5 Topics: Anti-Anxiety Agents; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Humans; Midazolam; Oxidoreductases, N-Demethylating; Predictive Value of Tests	2000
Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug metabolism and disposition: the biological fate of chemicals, 2001, Volume: 29, Issue:2 Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biliary Tract; Blotting, Western; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Interactions; Erythromycin; Intestinal Absorption; Intestines; Liver; Male; Midazolam; Oxidoreductases, N-Demethylating; Rats; Rats, Wistar; Rhodamine 123; Substrate Specificity; Verapamil	2001
Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug metabolism and disposition: the biological fate of chemicals, 2001, Volume: 29, Issue:4 Pt 1 Topics: Anesthetics, Intravenous; Animals; Aryl Hydrocarbon Hydroxylases; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Intestinal Absorption; Itraconazole; Kinetics; Liver; Male; Microsomes, Liver; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Portal Vein; Protein Binding; Rats; Rats, Sprague-Dawley; Tissue Distribution	2001
In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. The Journal of pharmacy and pharmacology, 2001, Volume: 53, Issue:5 Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Erythromycin; GABA Modulators; Kinetics; Liver; Male; Midazolam; Rats; Rats, Sprague-Dawley	2001
Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica; the fate of foreign compounds in biological systems, 2001, Volume: 31, Issue:5 Topics: Animals; Benzoflavones; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; GABA Modulators; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Intestines; Kinetics; Mice; Microsomes; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Nifedipine; Oxygen; Protein Binding; Steroid Hydroxylases; Terfenadine; Testosterone; Vasodilator Agents	2001
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. British journal of clinical pharmacology, 2002, Volume: 53, Issue:2 Topics: Adult; Drug Interactions; Erythromycin; Female; Humans; Hypnotics and Sedatives; Lidocaine; Liver Function Tests; Male; Midazolam; Time Factors	2002
Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals, 2003, Volume: 31, Issue:7 Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Azithromycin; Clarithromycin; Cytochrome P-450 CYP3A; Drug Interactions; Erythromycin; Humans; Hydroxylation; Macrolides; Microsomes, Liver; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Time Factors	2003
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics, 2003, Volume: 13, Issue:10 Topics: Adolescent; Adult; Anti-Anxiety Agents; Area Under Curve; Black or African American; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; Exons; Female; Genetic Variation; Genotype; Homozygote; Humans; Intestinal Mucosa; Liver; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Phenotype; Polymorphism, Genetic; Rifampin; White People	2003
Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica; the fate of foreign compounds in biological systems, 2004, Volume: 34, Issue:5 Topics: Administration, Oral; Animals; Antibodies; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Diltiazem; Drug Interactions; Enzyme Inhibitors; Erythromycin; Female; Humans; In Vitro Techniques; Ketoconazole; Kinetics; Macaca fascicularis; Microsomes, Liver; Midazolam; Models, Animal; Oxidoreductases, N-Demethylating	2004
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. Journal of the National Cancer Institute, 2004, Nov-03, Volume: 96, Issue:21 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Breath Tests; Camptothecin; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Confidence Intervals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Erythromycin; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Male; Midazolam; Middle Aged; Phenotype; Predictive Value of Tests; Prospective Studies	2004
Effect of ion suppression on judgment of enzyme inhibition and avoidance of error by utilizing a stable isotope-labeled probe substrate: example of CYP3A4 inhibition with [13C4,15N] labeled midazolam as a substrate. Drug metabolism and pharmacokinetics, 2007, Volume: 22, Issue:2 Topics: Artifacts; Carbon Isotopes; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextrorphan; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Erythromycin; Humans; Hydroxylation; In Vitro Techniques; Ketoconazole; Liver; Microsomes, Liver; Midazolam; Molecular Probes; Nitrogen Isotopes; Reproducibility of Results; Tandem Mass Spectrometry	2007
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:1 Topics: Adolescent; Adult; Animals; Baculoviridae; Blotting, Western; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; Female; Fluconazole; Genetic Vectors; Genotype; Humans; In Vitro Techniques; Insecta; Male; Microsomes, Liver; Midazolam; Middle Aged; Substrate Specificity; Transfection	2008
Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Current drug metabolism, 2007, Volume: 8, Issue:8 Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Interactions; Enzyme Inhibitors; Erythromycin; Fluconazole; Ketoconazole; Midazolam; Substrate Specificity; Verapamil	2007
Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:1 Topics: Algorithms; Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Gene Expression; Kinetics; Liver; Male; Membrane Proteins; Microsomes, Liver; Midazolam; Models, Biological; Rats; Rats, Sprague-Dawley	2010
Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. The Journal of veterinary medical science, 2009, Volume: 71, Issue:9 Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; Cats; Cimetidine; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Female; Half-Life; Hypnotics and Sedatives; Ketoconazole; Microsomes, Liver; Midazolam	2009
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenetics and genomics, 2010, Volume: 20, Issue:10 Topics: Biocatalysis; Cytochrome P-450 CYP3A; Erythromycin; Genetic Variation; Humans; Kinetics; Midazolam; Mutant Proteins; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Quinidine; Substrate Specificity; Testosterone	2010
Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clinical pharmacology and therapeutics, 2011, Volume: 89, Issue:5 Topics: Adult; Aged; Animals; Cell Line; Cohort Studies; Cytochrome P-450 CYP3A; Dogs; Erythromycin; Female; Genetic Variation; Homozygote; Humans; Male; Mice; Mice, Knockout; Midazolam; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Protein Transport; Young Adult	2011
Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats. Biopharmaceutics & drug disposition, 2012, Volume: 33, Issue:4 Topics: Animals; Area Under Curve; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Interactions; Erythromycin; Female; Humans; Male; Microsomes, Liver; Midazolam; Models, Biological; Rats; Sex Factors; Species Specificity	2012
Prolonged sedation related to erythromycin and midazolam interaction: a word of caution. Indian pediatrics, 2011, Nov-11, Volume: 48, Issue:11 Topics: Anti-Bacterial Agents; Child; Drug Interactions; Erythromycin; Humans; Hypnotics and Sedatives; Male; Midazolam	2011
Impact of POR28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and genomics, 2013, Volume: 23, Issue:3* Topics: Cytochrome P-450 CYP3A; Erythromycin; Female; Humans; Male; Midazolam; Phenotype	2013
CYP3A4 intron 6 C>T SNP (CYP3A422) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 2013, Volume: 14, Issue:2* Topics: Breath Tests; Cytochrome P-450 CYP3A; DNA; Erythromycin; Female; Humans; Injections, Intravenous; Introns; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide	2013
Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin. Biopharmaceutics & drug disposition, 2017, Volume: 38, Issue:7 Topics: Anti-Bacterial Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Kinetics; Midazolam; Nifedipine; Testosterone	2017
Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture. Drug metabolism and disposition: the biological fate of chemicals, 2020, Volume: 48, Issue:8 Topics: Adult; Alprazolam; Cells, Cultured; Coculture Techniques; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Erythromycin; Female; Glucuronosyltransferase; Hepatobiliary Elimination; Hepatocytes; Humans; Male; Midazolam; Middle Aged; Primary Cell Culture; Rifampin; Time Factors	2020